Passage BIO, Inc.
PASG · XNASCIK 1787297fmd_1HDG9Y969SDNEMG1XSA0Y6TSFEManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 31 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Research and development | 30 | 82 | 118 | 86 | 61 | 40 | 23 |
| Operating income | (37) | (113) | (186) | (138) | (108) | (70) | (49) |
| Interest and investment income | 1 | 1 | 0 | – | – | – | – |
| Other non-operating income (expense) | – | – | – | 2 | 6 | 6 | 4 |
| Income tax expense | – | – | – | – | – | 0 | 0 |
| Net income | (46) | (112) | (185) | (136) | (102) | (65) | (46) |